SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

The FDA issued a Complete Response Letter for Summits ivonescimab application in EGFR-mutated lung cancer, citing insufficient evidence of a statistically significant overall-survival benefit despite strong progression-free-survival results. Traders are debating the setbacks impact: some expect further selling and a longer regulatory path, while others see the AstraZeneca investment, cash runway and broader pipeline as support for the longer-term case.

L3Harris Technologies, Inc. engages in the provision of defense and commercial technologies across the air, land, sea, space, and cyber domains. It operates through the following segments: Communication Systems, Integrated Mission Systems, Space and Airborne Systems, and Aerojet Rocketdyne. The Communication Systems segment enables warfighters across all domains with solutions critical to mission success even in the most contested environments. The Integrated Mission Systems segment focuses on the differentiated mission capabilities and prime systems integration for the air, land, and sea domains. The Space and Airborne Systems segment provides full mission solutions as a prime and subsystem integrator in the space, airborne, and cyber domains. The Aerojet Rocketdyne segment includes propulsion, power and armament products and systems to U.S. government, including the DoD, National Aeronautics and Space Administration (“NASA”) and major aerospace and defense prime contractors. The company was founded in 1890 and is headquartered in Melbourne, FL.

L3Harris Technologies Inc

L3Harris is drawing attention after officials linked a nationwide FAA communications outage and flight disruptions to a router on its network, with investigators still determining whether the cause was defective equipment or installation/configuration problems. Traders debate potential liability and reputational damage versus whether the company is being made a scapegoat, while some see the selloff as a buying opportunity.

Dogecoin (DOGE) is a cryptocurrency . Users are able to generate DOGE through the process of mining. Dogecoin has a current supply of 156,752,062,860.16806072. The last known price of Dogecoin is 0.05689686 USD and is down -11.89 over the last 24 hours. It is currently trading on 1545 active market(s) with $1,128,721,930.78 traded over the last 24 hours. More information can be found at http://dogecoin.com/.

Dogecoin

Dogecoin is drawing attention amid a sharp crypto-market selloff, with traders describing persistent weakness and fresh multi-year lows. The conversation is split between bearish calls for further losses and holders buying the dip or anticipating a rebound, often tied to Bitcoin and broader crypto sentiment.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,112,050. The last known price of Bitcoin is 63,437.21016941 USD and is down -7.02 over the last 24 hours. It is currently trading on 12780 active market(s) with $45,086,253,428.50 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins steep selloff and volatile rebound dominate discussion, with traders citing spot ETF outflows and leveraged liquidations as pressures. Bears expect further declines, while bulls see oversold conditions and dip-buying as signs a bounce could continue.

Algorand (ALGO) is a cryptocurrency launched in 2019. Algorand has a current supply of 10,000,000,000 with 9,079,921,637.950731 in circulation. The last known price of Algorand is 0.07697008 USD and is down -9.60 over the last 24 hours. It is currently trading on 586 active market(s) with $68,192,697.70 traded over the last 24 hours. More information can be found at http://algorand.foundation.

Algorand

Traders are debating whether ALGO has bottomed after a steep decline, with bulls pointing to support, rebound patterns, and potential altcoin-season upside while bears warn that the bounce may fail and further losses remain possible. Post-quantum security and tokenization are cited as longer-term bullish theses, but the conversation is chiefly about price direction and accumulation near recent lows.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Attention is centered on Omeros upcoming quarterly results, with traders watching whether U.S. YARTEMLEA sales continue to ramp after its launch and recent reimbursement milestones. Bullish posters expect strong commercial momentum, while others warn that sales expectations may be optimistic and debate whether the report will justify a higher valuation.

Ethereum (ETH) is a cryptocurrency . Ethereum has a current supply of 122,218,624.4003947. The last known price of Ethereum is 1,739.90377069 USD and is down -9.84 over the last 24 hours. It is currently trading on 14359 active market(s) with $18,820,901,710.98 traded over the last 24 hours. More information can be found at https://www.ethereum.org/.

Ethereum

Ethereum is under heavy selling pressure alongside Bitcoin and the broader crypto market, with traders pointing to forced liquidations and weak demand as the selloff deepens. The community is split between calling the decline a capitulation and buying opportunity and warning that prices could fall further.

Worldcoin (WLD) is a cryptocurrency launched in 2023and operates on the Ethereum platform. Worldcoin has a current supply of 10,000,000,000 with 3,785,317,463.598902 in circulation. The last known price of Worldcoin is 0.25340812 USD and is down -14.02 over the last 24 hours. It is currently trading on 594 active market(s) with $288,215,183.49 traded over the last 24 hours. More information can be found at https://worldcoin.org/.

Worldcoin

Worldcoin is drawing attention after a rally that traders link to OpenAIs confidential IPO filing and renewed interest in proof-of-human identity for AI agents. The community is split between viewing the AI connection as a longer-term catalyst and arguing the IPO is only a speculative association, with some also pointing to selling by Arthur Hayes as a cautionary signal.

ProShares Trust II - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

Debate centers on SCOs exposure to volatile crude prices amid Iran-war and Strait of Hormuz headlines, with traders buying the inverse ETF on hopes of de-escalation, resumed supply and lower oil. Many others complain that daily resets and futures-curve effects have eroded returns and that SCO has not risen as much as they expected when crude fell.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candels planned prostate-cancer BLA submission was pushed to mid-2027 as the company refines assays amid ongoing FDA discussions, driving a sharp selloff. Traders are divided between viewing the CMC issue as a fixable manufacturing hurdle that leaves the clinical data intact and worrying about execution, management credibility, and possible dilution.

statis crypto Watchlist

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$VELO We got here faster than I anticipated. The biggest itch I have right now is how they blatantly went from “all is looking good” for positive EBITDA to delaying it with between 18 and 28 months. End of year 2028 would mean more than 2 years wait to see those numbers.
Maybe that is the whole thing right? They can’t scale their business without the new facility. And they don’t have money for the new facility, so they know it will take the better part of next year to get into that position.
That gives us 2028. The year when they have ability to ramp up orders and actually hit the 40 million quarterly revenues that they need for positive EBITDA.
I don’t know what to make of it other than this. I sold most at earnings pre market at 5.6 and I’m not a buyer until Arun starts to answer questions better than a 5th grader. 
I really want them to succeed and to buy back in heavier but even at $3 I think we’re looking at a painful 2027

Dean

$VELO So with all that said, and with me still owning all the shares I bought over the year, I anticipate that we will go down heavily today and for some weeks. I don&#39;t think it&#39;s strange if we&#39;ll hover around high 3s to low 4s soon. I am too looking forward to getting over 10, and then hopefully back to levels around 15-20 but I just don&#39;t see that happening anytime soon. That would require some type of messiah PR involving Space X.

StockTwits Web

Velo3D Inc

James

StockTwits for iOS

 We got here faster than I anticipated. The biggest itch I have right now is how they blatantly went from “all is looking good” for positive EBITDA to delaying it with between 18 and 28 months. End of year 2028 would mean more than 2 years wait to see those numbers.
Maybe that is the whole thing right? They can’t scale their business without the new facility. And they don’t have money for the new facility, so they know it will take the better part of next year to get into that position.
That gives us 2028. The year when they have ability to ramp up orders and actually hit the 40 million quarterly revenues that they need for positive EBITDA.
I don’t know what to make of it other than this. I sold most at earnings pre market at 5.6 and I’m not a buyer until Arun starts to answer questions better than a 5th grader. 
I really want them to succeed and to buy back in heavier but even at $3 I think we’re looking at a painful 2027

@TheQuietBullx  
 
 Agree ! 
 
Let&#39;s make it simple.  
  
Look at what they said 3 months ago, at the time of the 2nd Qtr report.  (stock closed at $16.16 on August 14th)  
  
stocktwits.com/news-article...  
  
Look at how the market trashed the stock price (IT CLOSED AT $4.15 PER SHARE YESTERDAY) after they disclosed in the 3rd QTR report that:  
  
1.  They will burn cash until 2028.  (IMO they will be bankrupt in 2028 or at best case, they will again post-pone the year during which they will stop BURNING CASH)  
  
2.  They will NOT achieve gross margin of 30% + this year.  (hint...lower operating costs is part of the equation leading to the cessation of the cash burn)  
  
3.  They are having problems scaling up (think S curve) the Livermore factory (Forge 1), they don&#39;t even have the power upgrade necessary to operate it....you don&#39;t think that electrical upgrade problem existed 3 months ago, when they pumped their 2nd Qtr results and said Forge 1 will enable them to triple capacity?

  
 
 Agree ! 
 
Let's make it simple.  
  
Look at what they said 3 months ago, at the time of the 2nd Qtr report.  (stock closed at $16.16 on August 14th)  
  


...  
  
Look at how the market trashed the stock price (IT CLOSED AT $4.15 PER SHARE YESTERDAY) after they disclosed in the 3rd QTR report that:  
  
1.  They will burn cash until 2028.  (IMO they will be bankrupt in 2028 or at best case, they will again post-pone the year during which they will stop BURNING CASH)  
  
2.  They will NOT achieve gross margin of 30% + this year.  (hint...lower operating costs is part of the equation leading to the cessation of the cash burn)  
  
3.  They are having problems scaling up (think S curve) the Livermore factory (Forge 1), they don't even have the power upgrade necessary to operate it....you don't think that electrical upgrade problem existed 3 months ago, when they pumped their 2nd Qtr results and said Forge 1 will enable them to triple capacity?